Multiparticulates of spray-coated drug and polymer on a meltable core
A pharmaceutical composition comprises multiparticulates comprising a melt-congeal core and a solid amorphous dispersion layer of a poorly water soluble drug and polymer. The multiparticulates are suitable for improving bioavailability of poorly water soluble drugs. The melt-congeal cores facilitate application of the solid amorphous dispersion layer, and allow incorporation of additional optional components to the core so as to adjust the release of drug from the multiparticulate.
1. A pharmaceutical composition comprising multiparticulates, the multiparticulates comprising:
(a) a melt-congeal core comprising a matrix material present in an amount of at least 30 wt % of said core, said matrix material being solid at 25° C. and having a melt temperature of less than 200° C., wherein said matrix material is selected from the group consisting of waxes, long chain alcohols, fatty acid esters, glycolized fatty acid esters, phosphoglycerides, polyoxyethylene alkyl ethers, long chain carboxylic acids, sugar alcohols, and mixtures thereof, wherein the melt-congeal core further comprises a dissolution enhancer or a dissolution-inhibiting agent; and
(b) a solid amorphous dispersion layer coating said melt-congeal core, said solid amorphous dispersion layer comprising a drug and a polymer, wherein the matrix material and the polymer are not the same compound, wherein at least 75 wt % of said drug in said solid amorphous dispersion layer is amorphous and wherein at least a portion of said solid amorphous dispersion layer is in the form of a substantially homogeneous solid solution, and wherein said solid solution exhibits a single glass-transition temperature;
wherein the weight of said solid amorphous dispersion layer ranges from 1 wt % to 90 wt % of said multiparticulates.
2. The composition of claim 1 wherein said matrix material is present in said melt-congeal core in an amount of at least 80 wt % of said melt-congeal core.
3. The composition of claim 1 wherein said melt-congeal core further comprises a swelling agent.
4. The composition of claim 1 wherein said melt-congeal core further comprises said drug.
5. The composition of claim 1 wherein said melt-congeal core further comprises a second drug.
6. The composition of any of claim 1 , 2 , 3 , or 4 wherein at least 90 wt % of said drug in said amorphous dispersion layer is amorphous.
7. The composition of claim 6 wherein said polymer is selected from the group consisting of polyvinylpyrrolidone, hydroxypropyl methyl cellulose, hydroxypropyl methyl cellulose acetate succinate, cellulose acetate phthalate, cellulose acetate trimellitate, and carboxymethyl ethyl cellulose.
8. The composition of claim 1 wherein said melt temperature is from 50° C. to 150° C.
9. The composition of claim 1 wherein said melt-congeal core has a volume weighted mean diameter of less than about 150 μm.
10. The composition of claim 1 wherein said multiparticulates have a volume weighted mean diameter of less than 300 μm.
11. The composition of claim 1 further comprising an exterior coating surrounding said solid amorphous dispersion layer, the exterior coating being formed of a material different from the solid amorphous dispersion layer material.